Overall, by introducing a novel, PP2A-dependent tumor suppressor checkpoint, Patel et al. identified the cooperative role of concomitantly inactivated Spry2, PTEN, and PP2A to drive the prostate cancer progression. This evidence concerns the gene SPRY2 and prostate cancer.